Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics (SLNO)
:SLNO
Total Valuation
Soleno Therapeutics has a market cap or net worth of $4.51B. The enterprise value is $4.13B.
Market Cap$4.51B
Enterprise Value$4.13B
Share Statistics
Soleno Therapeutics has 52,746,872 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,746,872
Owned by Insiders10.12%
Owned by Institutions0.65%
Financial Efficiency
Soleno Therapeutics’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -58.97%.
Return on Equity (ROE)-0.72
Return on Assets (ROA)-0.53
Return on Invested Capital (ROIC)-58.97%
Return on Capital Employed (ROCE)-0.59
Revenue Per Employee0.00
Profits Per Employee-1.53M
Employee Count115
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio16.49
Price to Fair Value7.37
Price to FCF-46.67
Price to Operating Cash Flow-42.87
PEG Ratio2.29
Income Statement
In the last 12 months, Soleno Therapeutics had revenue of 0.00 and earned -175.85M in profits. Earnings per share was -4.38.
Revenue0.00
Gross Profit0.00
Operating Income-184.43M
Pretax Income-175.85M
Net Income-175.85M
EBITDA-173.63M
Earnings Per Share (EPS)-4.38
Cash Flow
In the last 12 months, operating cash flow was -89.32M and capital expenditures -212.00K, giving a free cash flow of -89.53M billion.
Operating Cash Flow-89.32M
Free Cash Flow-89.53M
Free Cash Flow per Share-1.70
Dividends & Yields
Soleno Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.53
52-Week Price Change86.63%
50-Day Moving Average79.24
200-Day Moving Average59.97
Relative Strength Index (RSI)61.35
Average Volume (3m)1.27M
Important Dates
Soleno Therapeutics upcoming earnings date is Aug 6, 2025, TBA (Confirmed).
Last Earnings DateMay 7, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Soleno Therapeutics as a current ratio of 15.68, with Debt / Equity ratio of 1.27%
Current Ratio15.68
Quick Ratio15.68
Debt to Market Cap0.03
Net Debt to EBITDA0.20
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Soleno Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Soleno Therapeutics EV to EBITDA ratio is -10.20, with an EV/FCF ratio of -25.55.
EV to Sales0.00
EV to EBITDA-10.20
EV to Free Cash Flow-25.55
EV to Operating Cash Flow-25.63
Balance Sheet
Soleno Therapeutics has $289.95M in cash and marketable securities with $2.96M in debt, giving a net cash position of -$286.99M billion.
Cash & Marketable Securities$289.95M
Total Debt$2.96M
Net Cash-$286.99M
Net Cash Per Share-$5.44
Tangible Book Value Per Share$5.93
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Soleno Therapeutics is $110.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$110.78
Price Target Upside26.40% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast―
EPS Growth Forecast-43.20%